Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug

An infant hemangioma and detection kit technology, applied in the biological field, can solve the problem of lack of predictive serum early warning proteins, and achieve the effects of promoting angiogenesis of hemangioma stem cells, reducing the rate of teratogenicity, and reducing the rate of misdiagnosis and mistreatment

Inactive Publication Date: 2019-10-29
江成鸿
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows researchers studying fetal bovine tissue to discover how certain proteins called CD93 play crucial roles during pregnancy when they detect signs of abnormalities such as IUH. These findings help healthcare providers better diagnose and treat patients with serious conditions like acute lymphoblasia caused by virus infection.

Problems solved by technology

This patented technical problem addressed in this patents relates to finding out potential biomarkers from amniotic fluid during pregnancy or breastfeeding periods due to their ability to detect abnormalities earlier compared to older individuals who develop symptoms later when examining them.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug
  • Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug
  • Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1. Neonatal umbilical cord blood serum CD93 plays an important role in predicting / predicting the occurrence of IH

[0024] In order to search for early warning proteins in cord blood, the following experimental specimens were collected and studied:

[0025] 1. From 2014 to 2016, about 1,100 newborn cord blood serum samples were reserved for prospective collection and stored in a -80°C refrigerator. During the experiment, the samples were avoided from repeated freezing and thawing.

[0026] 2. Each newborn was observed and followed up for half a year, and a total of 12 children with IH were found, so the reserved serum samples were divided into two groups: the experimental group with IH (follow-up with positive cord blood serum) and the control without IH group (follow-up negative cord blood serum).

[0027] 3. Using Label-free quantitative proteomics technology (Label-free quantitative proteomics technology) to conduct quantitative mass spectrometry detection o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of CD93 in the preparation of an early warning infantile hemangioma (IH) umbilical blood assay kit and a therapeutic drug. A study found that the neonatal umbilical blood serum CD93 has an important role in predicting/warning IH, and is a serum marker of IH tumors. Because IH is the most common benign tumor in infants, and the neonatal umbilical blood is easy to sufficiently collect in the early stage of IH, has no trauma, and is easy to be accepted by family members, the development of using CD93 as a umbilical blood assay kit or test paper for predicting/warning protein for warning the occurrence of IH has extremely important clinical significance and social values on the early monitoring, the early detection and the early treatment of IH, minimizing the teratogenesis rate of severe IH, and reducing the rate of misdiagnosis and mistreatment. In addition, the CD93, as transmembrane protein, can promote angiogenesis of hemangioblast stem cells, has important significance in anti-angiogenesis therapeutic targets, and can be used for preparing related therapeutic drugs and preventive drugs for early treatment and prevention of IH.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner 江成鸿
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com